Skip to main content

Moxifloxacin FDA Alerts

The FDA Alerts below may be specifically about moxifloxacin or relate to a group or class of drugs which include moxifloxacin.

MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.

Recent FDA Alerts for moxifloxacin

Edge Pharma, LLC Issues Voluntary Nationwide Recall of All Drug Products Due to Lack of Sterility Assurance

December 4, 2021 – Colchester, VT, Edge Pharma, LLC is voluntarily recalling all lots of all drugs compounded at Edge Pharma, LLC to the consumer level. All products are being recalled due to process issues that could lead to a lack of sterility assurance for products intended to be sterile and could impact the safety and quality of non-sterile products.

Risk Statement: Administration of a drug product intended to be sterile, that is not sterile, could result in site specific infections as well as serious systemic infections which may be life- threatening. To date, Edge Pharma, LLC has not received and is not aware of any adverse events related to this recall.

The products are used for a variety of indications and are packaged in Containers, IV bags, Syringes, Drop containers, Vials, Bottles, and Jars. The affected lots and expiration dates are included in the link listed below. The names and concentration of the drugs are listed in the table following this release.

LINK TO LOT NUMBERS, DISTRIBUTION DATES & DRUG INFORMATION WILL BE ACTIVE ON 12-08-21.

https://edgepharma.com/assets/recalledproducts.pdf

The recall encompasses all compounded sterile and nonsterile drug products, within expiry, that were dispensed from Edge Pharma, LLC. The products subject to this recall were distributed nationwide and directly to customers and/or medical facilities. The products can be identified by the label containing the Edge Pharma, LLC name and logo.

Edge Pharma, LLC is notifying its customers by email, Media and FDA alerts, and direct outreach. Consumers and institutions that have Edge Pharma, LLC products should stop using the products immediately and may either return or discard the recalled lots.

Consumers with questions regarding this recall can contact Edge Pharma, LLC by phone number or e-mail address on Monday-Friday from 8:00 am to 4:00 pm, EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

STERILE PRODUCTS NDC
ALUMINUM POTASSIUM SULFATE CONCENTRATED (PF) 300 G/300 ML 05446-0637-03
BUFFERED LIDOCAINE HCL (PF) 1% 05446-0850-10
BUFFERED LIDOCAINE HCL / EPINEPHRINE SOLUTION (PF) 1% / 1:100,000 05446-1268-01
CEFTAZIDIME (PF) 22.5 MG/ML 05446-0733-01
CEFUROXIME OPHTHALMIC SOLUTION (PF) 10 MG/ML 05446-1003-01
DEXAMETHASONE PHOSPHATE (PF) 24 MG/ML 05446-0848-01
EDETATE DISODIUM (EDTA) (PF) 1.5% 05446-1427-10
EDETATE DISODIUM (EDTA) (PF) 3% 05446-1428-10
EPINEPHRINE / LIDOCAINE HCL (PF) 0.025% / 0.75% 05446-0863-01
GEMCITABINE (PF) 20 MG/ML 05446-1566-50
GLYCERIN, STERILE (PF) 99% 05446-1486-03
LIDOCAINE HCL / BUPIVACAINE HCL / HYALURONIDASE (PF) 2% / 0.375% / 15 UNITS/ML 05446-1548-18
METHACHOLINE CHALLENGE 5 SYRINGE TEST KIT 05446-1600-05
METHACHOLINE CHLORIDE (PF) 16 MG/ML 05446-1241-01
METHACHOLINE CHLORIDE (PF) 4 MG/ML 05446-1246-01
METHACHOLINE CHLORIDE (PF) 1 MG/ML 05446-1247-01
METHACHOLINE CHLORIDE (PF) 0.25 MG/ML 05446-1248-01
METHACHOLINE CHLORIDE (PF) 0.0625 MG/ML 05446-1249-01
METHOTREXATE (PF) 125 MG/5ML 05446-1505-05
MITOMYCIN IRRIGATION (PF) 1 MG/ML 05446-1416-01
MITOMYCIN-C (PF) 0.4 MG/ML 05446-1009-01
MITOMYCIN-C (PF) 0.2 MG/ML 05446-1011-01
MOXIFLOXACIN HCL (PF) 1 MG/ML 05446-1050-01
MVASI 3.75MG/0.15ML (25 MG/ML) 05446-1661-13
NEOSTIGMINE METHYLSULFATE 1 MG/ML 05446-1549-05
NOREPINEPHRINE BITARTRATE 8 MG/250ML 05446-1179-03
PHENOL, STERILE (PF) 6% 05446-1476-05
PHENYLEPHRINE / TROPICAMIDE / KETOROLAC / CIPROFLOXACIN (PF) 10% / 1% / 0.125% / 0.3% 05446-1270-01
PHENYLEPHRINE HCL 0.1 MG/ML 05446-1544-10
PHENYLEPHRINE HCL 0.1 MG/ML 05446-1545-05
PHENYLEPHRINE HCL (PF) 800 MCG/10 ML 05446-1652-01
PHENYLEPHRINE HCL (PF) 20 MG/ 250 ML 05446-1667-01
PHENYLEPHRINE HCL / LIDOCAINE HCL (PF) 1.5% / 1% 05446-1118-01
PHENYLEPHRINE HCL / TROPICAMIDE 2.5% / 1% 05446-0815-01
PHENYLEPHRINE/ CYCLOPENTOLATE / TROPICAMIDE / KETOROLAC 10% / 0.25% / 0.25% / 0.125% 05446-0859-03
PHENYLEPHRINE/ CYCLOPENTOLATE / TROPICAMIDE / KETOROLAC (PF) 2.5% / 0.25% / 0.25% / 0.125% 05446-0993-01
POVIDONE-IODINE (PF) 5% 05446-1680-01
TRYPAN BLUE (PF) 0.03% 05446-1200-01
VANCOMYCIN HCL (PF) 10 MG/ML 05446-0736-01
VANCOMYCIN HCL (PF) 1250 MG/250ML 05446-1456-01
VANCOMYCIN HCL (PF) 1500 MG/512ML 05446-1458-01
VANCOMYCIN HCL (PF) 1750 MG/514ML 05446-1459-01
STERILE PRODUCTS NDC
PRESCRIPTION ALLERGY TREATMENT SETS DISTRIBUTED BETWEEN 12-02-20 to 12-01-21 N/A
NON-STERILE PRODUCTS NDC
BENZOCAINE / LIDOCAINE / TETRACAINE 20% / 8% / 4% 05446-1235-01
CANTHARIDIN 0.7% 05446-0572-03
CANTHARIDIN PLUS 1% / 30% 05446-0970-03
CIPROFLOXACIN / SULFACETAMIDE SODIUM / AMPHOTERICIN B 30MG / 50MG / 5MG 05446-1633-01
CIPROFLOXACIN / SULFACETAMIDE SODIUM / AMPHOTERICIN B /
HYDROCORTISONE 30MG / 50MG / 5MG / 25MG
05446-1634-01
DEXAMETHASONE IONTOPHORESIS 0.4% 05446-0622-01
DIBUTYL SQUARATE 2% 05446-1047-03
DIBUTYL SQUARATE 1% 05446-1156-03
LIDOCAINE / TETRACAINE 23% / 7% 05446-1647-01
LIDOCAINE HCL / EPINEPHRINE / TETRACAINE HCL (LET) 4%/0.05%/0.5% 05446-0607-01
LIDOCAINE HCL / OXYMETAZOLINE 4% / 0.05% 05446-1256-01
LIDOCAINE HCL / PRILOCAINE HCL / TETRACAINE HCL
(PROFOUND) DENTAL (RASPBERRY MARSHMALLOW) 10% / 10% / 4%
05446-0790-10
LIDOCAINE HCL / PRILOCAINE HCL / TETRACAINE HCL
(PROFOUND) DENTAL GEL (MINT) 10% / 10% / 4%
05446-0407-10
LIDOCAINE HCL / PRILOCAINE HCL / TETRACAINE HCL /
PHENYLEPHRINE HCL (PROFOUND-PE) DENTAL (RASPBERRY MARSHMALLOW) 10% / 10% / 4% / 2%
05446-1018-10
LIDOCAINE HCL / PRILOCAINE HCL / TETRACAINE HCL /
PHENYLEPHRINE HCL (PROFOUND-PE) DENTAL GEL (MINT) 10% / 10% / 4% / 2%
05446-0408-10
PHENOL 89% 05446-1211-03
PHENYLEPHRINE HCL / LIDOCAINE HCL 1% / 4% 05446-1045-03
PHYTONADIONE (VITAMIN K) 5 MG/ML 05446-1132-03
PROMETHAZINE HCL 25 MG / 1.2ML 05446-1341-01
TETRACAINE HCL 4% 05446-1195-03
VANCOMYCIN HCL 125 MG / 2.5ML (50 MG/ML) 05446-1348-01

Source: FDA


Fluoroquinolone Antibiotics: Safety Communication - Increased Risk of Ruptures or Tears in the Aorta Blood Vessel in Certain Patients

ISSUE: FDA review found that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the main artery of the body, called the aorta.  These tears, called aortic dissections, or ruptures of an aortic aneurysm can lead to dangerous bleeding or even death.  They can occur with fluoroquinolones for systemic use given by mouth or through an injection.

BACKGROUND: Fluoroquinolone antibiotics are approved to treat certain bacterial infections and have been used for more than 30 years.  They work by killing or stopping the growth of bacteria that can cause illness.  Without treatment, some infections can spread and lead to serious health problems.

List of Currently Available FDA-Approved Systemic Fluoroquinolones

+ available as generic
* available only as generic

RECOMMENDATION:
Healthcare professionals should:

  • Avoid prescribing fluoroquinolone antibiotics to patients who have an aortic aneurysm or are at risk for an aortic aneurysm, such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers-Danlos syndrome, and elderly patients. 

  • Prescribe fluoroquinolones to these patients only when no other treatment options are available. 

  • Advise all patients to seek immediate medical treatment for any symptoms associated with aortic aneurysm. 

  • Stop fluoroquinolone treatment immediately if a patient reports side effects suggestive of aortic aneurysm or dissection.

Patients should:

  • Seek medical attention immediately by going to an emergency room or calling 911 if you experience sudden, severe, and constant pain in the stomach, chest or back. 

  • Be aware that symptoms of an aortic aneurysm often do not show up until the aneurysm becomes large or bursts, so report any unusual side effects from taking fluoroquinolones to your health care professional immediately. 

  • Inform your health professional before starting an antibiotic prescription,  if you have a history of aneurysms, blockages or hardening of the arteries, high blood pressure, or genetic conditions such as Marfan syndrome or Ehlers-Danlos syndrome. 

  • Do not stop the antibiotic without first talking to your health care professional.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

[12/20/2018 - Drug Safety Communication - FDA]


Fluoroquinolone Antibiotics: FDA Requires Labeling Changes Due to Low Blood Sugar Levels and Mental Health Side Effects

ISSUE: FDA is strengthening the current warnings in the prescribing information that fluoroquinolone antibiotics may cause significant decreases in blood sugar and certain mental health side effects.

BACKGROUND:
Fluoroquinolone antibiotics are approved to treat certain serious bacterial infections, and have been used for more than 30 years. They work by killing or stopping the growth of bacteria that can cause illness. Without treatment, some infections can spread and lead to serious health problems.

Most fluoroquinolone antibiotic drug labels include a warning that blood sugar disturbances, including high blood sugar and low blood sugar and depending on the fluoroquinolone antibiotic class, a range of mental health side effects are already described under Central Nervous System Effects in the Warnings and Precautions section of the drug label, which differed by individual drug.

RECOMMENDATION: The new label changes will add that low blood sugar levels, also called hypoglycemia, can lead to coma and the new label will also make the mental health side effects more prominent and more consistent across the systemic fluoroquinolone drug class. The mental health side effects to be added to or updated across all the fluoroquinolones are:

  • disturbances in attention

  • disorientation

  • agitation

  • nervousness

  • memory impairment

  • serious disturbances in mental abilities called delirium.

FDA continues to monitor and evaluate the safety and effectiveness of medicines after we approve them and they go on the market. In the case of fluoroquinolones, we reviewed reports of cases submitted to FDA and the published medical literature of apparently healthy patients who experienced serious changes in mood, behavior, and blood sugar levels while being treated with systemic fluoroquinolones.

Patients should tell your health care professionals if you are taking a diabetes medicine when your health care professional is considering prescribing an antibiotic, and also if you have low blood sugar or symptoms of it while taking a fluoroquinolone. For patients with diabetes, your health care professional may ask you to check your blood sugar more often while taking a fluoroquinolone. Early signs and symptoms of low blood sugar include:

  • confusion

  • pounding heart or very fast pulse

  • dizziness

  • pale skin

  • feeling shaky

  • sweating

  • unusual hunger

  • trembling

  • headaches

  • weakness

  • irritability

  • unusual anxiety

Health care professionals should be aware of the potential risk of hypoglycemia sometimes resulting in coma, occurring more frequently in the elderly and those with diabetes taking an oral hypoglycemic medicine or insulin.

  • Alert patients of the symptoms of hypoglycemia and carefully monitor blood glucose levels in these patients, and discuss with them how to treat themselves if they have symptoms of hypoglycemia.

  • Inform patients about the risk of psychiatric adverse reactions that can occur after just one dose.

  • Stop fluoroquinolone treatment immediately if a patient reports any central nervous system side effects, including psychiatric adverse reactions, or blood glucose disturbances and switch to a non-fluoroquinolone antibiotic if possible.

  • Stop fluoroquinolone treatment immediately if a patient reports serious side effects involving the tendons, muscles, joints, or nerves, and switch to a non-fluoroquinolone antibiotic to complete the patient’s treatment course.

Health care professionals should not prescribe fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections because the risks outweigh the benefits in these patients.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

[07/2016 - www.fda.gov/Drugs/DrugSafety/ucm500143.htm
[05/2016 - www.fda.gov/Drugs/DrugSafety/ucm511530.htm


Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects

ISSUE: FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection).

Includes the following currently available fluoroquinolones:

These medicines are associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient. As a result, FDA revised the Boxed Warning, FDA’s strongest warning, to address these serious safety issues. In addition, FDA updated other parts of the drug label including the Warnings and Precautions and Medication Guide sections.

FDA has determined that fluoroquinolones should be reserved for use in patients who have no other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections because the risk of these serious side effects generally outweighs the benefits in these patients. For some serious bacterial infections the benefits of fluoroquinolones outweigh the risks, and it is appropriate for them to remain available as a therapeutic option.

FDA is continuing to assess safety issues with fluoroquinolones as part of FDA’s usual ongoing review of drugs and will update the public if additional actions are needed. See the FDA Drug Safety Communication for additional information, including a Data Summary and Additional Information for Health Care Professionals and Patients.

BACKGROUND: The labels of fluoroquinolone medicines already have a Boxed Warning for tendinitis, tendon rupture, and worsening of myasthenia gravis. The labels also include warnings about the risks of peripheral neuropathy and central nervous system effects. Other serious risks associated with fluoroquinolones are described in the labels, such as cardiac, dermatologic, and hypersensitivity reactions. After FDA’s 2013 review that led to the additional warning that peripheral neuropathy may be irreversible, FDA evaluated post-marketing reports of apparently healthy patients who experienced disabling and potentially permanent side effects involving two or more body systems after being treated with a systemic fluoroquinolone

RECOMMENDATION: Patients must contact your health care professional immediately if you experience any serious side effects while taking your fluoroquinolone medicine. Some signs and symptoms of serious side effects include unusual joint or tendon pain, muscle weakness, a “pins and needles” tingling or pricking sensation, numbness in the arms or legs, confusion, and hallucinations. Talk with your health care professional if you have any questions or concerns (see List of Serious Side Effects from Fluoroquinolones in the FDA Drug Safety Communication).

Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients. Stop fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

[07/26/2016 - Drug Safety Communication - FDA]


Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections

ISSUE: FDA is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options.

An FDA safety review has shown that fluoroquinolones when used systemically (i.e. tablets, capsules, and injectable) are associated with disabling and potentially permanent serious side effects that can occur together. These side effects can involve the tendons, muscles, joints, nerves, and central nervous system.

As a result, FDA is requiring the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs to be updated to reflect this new safety information. FDA is continuing to investigate safety issues with fluoroquinolones and will update the public with additional information if it becomes available.

See the FDA Drug Safety Communication for a list of currently available FDA approved fluoroquinolones for systemic use.

BACKGROUND: The safety issues described in the Drug Safety Communication were also discussed at an FDA Advisory Committee meeting in November 2015.

RECOMMENDATION: Patients should contact your health care professional immediately if you experience any serious side effects while taking your fluoroquinolone medicine. Some signs and symptoms of serious side effects include tendon, joint and muscle pain, a “pins and needles” tingling or pricking sensation, confusion, and hallucinations. Patients should talk with your health care professional if you have any questions or concerns.

Health care professionals should stop systemic fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

[05/12/2016 - Drug Safety Communication - FDA]
 


Fluoroquinolone Antibacterial Drugs: Drug Safety Communication- Risk for possibly permanent nerve damage

ISSUE: FDA has required the drug labels and Medication Guides for all fluoroquinolone antibacterial drugs be updated to better describe the serious side effect of peripheral neuropathy. This serious nerve damage potentially caused by fluoroquinolones may occur soon after these drugs are taken and may be permanent.

BACKGROUND: The risk of peripheral neuropathy occurs only with fluoroquinolones that are taken by mouth or by injection.  Approved fluoroquinolone drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive).  The topical formulations of fluoroquinolones, applied to the ears or eyes, are not known to be associated with this risk.

RECOMMENDATION: Make sure your patients know to contact you if they develop symptoms of peripheral neuropathy. Make sure your patients receive the Medication Guide with every prescription. If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped, and the patient should be switched to another, non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

[08/15/2013 – www.fda.gov/Drugs/DrugSafety/ucm365050.htm


Fluoroquinolone Antimicrobial Drugs

[Posted 07/08/2008] FDA notified healthcare professionals that a BOXED WARNING and Medication Guide are to be added to the prescribing information to strengthen existing warnings about the increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolones for systemic use.

Fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture. This risk is further increased in those over age 60, in kidney, heart, and lung transplant recipients, and with use of concomitant steroid therapy. Physicians should advise patients, at the first sign of tendon pain, swelling, or inflammation, to stop taking the fluoroquinolone, to avoid exercise and use of the affected area, and to promptly contact their doctor about changing to a non-fluoroquinolone antimicrobial drug. Selection of a fluoroquinolone for the treatment or prevention of an infection should be limited to those conditions that are proven or strongly suspected to be caused by bacteria.

[July 08, 2008 - Information for Healthcare Professionals - FDA]
[July 08, 2008 - News Release - FDA]


More moxifloxacin resources